Erytech Pharma Reported Cash And Cash Equivalents Of $33.7M At End Of March 2023
$ERYP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Erytech Pharma Reported Cash And Cash Equivalents Of $33.7M At End Of March 2023
Save time and jump to the most important pieces.
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023 All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy Lyon (France), June 23, 2023 – ERYTECH Pharma ((Euronext Paris &, NASDAQ:ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023 The adopted resolutio
ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (NASDAQ:ERYP) announces the filing of a new lawsuit by Akkadian Partners. Despite the rejection by the President of the Lyon Commercial Court of Akkadian Partners' request to postpone the General Meeting's vote on the proposed merger, Akkadian has initiated new legal proceedings with the clear aim of continuing its attempt to destabilize Erytech. As part of this new procedure, the first hearing of which will take place after the vote on the merger, Akkadian Partners is requesting the cancellation of the capit
ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar Cambridge, MA (U.S.) and Lyon (France), April 28, 2022 – ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the "Autorité des Marchés Financiers" (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities an
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023 All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy Lyon (France), June 23, 2023 – ERYTECH Pharma ((Euronext Paris &, NASDAQ:ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023 The adopted resolutio
SC 13G/A - Erytech Pharma S.A. (0001624422) (Subject)
SC 13G/A - Erytech Pharma S.A. (0001624422) (Subject)
SC 13G/A - Erytech Pharma S.A. (0001624422) (Subject)
ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar Cambridge, MA (U.S.) and Lyon (France), April 28, 2022 – ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the "Autorité des Marchés Financiers" (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities an
ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update Lyon (France) and Cambridge, MA (U.S.), September 15, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2021 conference call and webcast on Tuesday, September 21, 2021, at 2:30 PM CEST/8:30 AM ET to discuss operational highlights. The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/6866536 (Conference ID : 6866536)Once registered, parti
All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy
In February, Erytech Pharma SA (NASDAQ:ERYP) announced its proposed combination with Pherecydes Pharma S.A. In June, Erytech announced that Akkadian initiated proceedings to postpone the vote, scheduled on 23 June, on the merger with Pherecydes. The merger would see Pherecydes absorbed into publicly listed Erytech, with Pherecydes shareholders receiving 15 new Erytech shares for every four of their current shares. Monday, Erytech Pharma responded to what it described as Akkadian Partners' "disinformation," arguing that the investor's challenge to the merger was "based on incomplete information and misleading arguments." Akkadian Partners owns around 5% of Erytech's stock. Erytech warned
Gainers Audacy, Inc. (NYSE:AUD) gained 75.8% to $0.2337 in pre-market trading after gaining around 16% on Wednesday. The company posted upbeat quarterly sales. Polar Power, Inc. (NASDAQ:POLA) gained 68% to $1.73 in pre-market trading after the company unveiled new line of mobile electric vehicle chargers. MMTec, Inc. (NASDAQ:MTC) gained 44.2% to $1.50 in pre-market trading after gaining around 8% on Wednesday. Tivic Health Systems, Inc. (NASDAQ:TIVC) jumped 27.3% to $0.2098 in pre-market trading after gaining 7% on Wednesday. Tivic Health launched a B2B portal. Ampio Pharmaceuticals, Inc. (NYSE:AMPE) surged 24.8% to $0.2521 in pre-market trading after declining around 5% on Wednesday